Metformin in patients with chronic kidney disease: Strengths and weaknesses

Journal of Nephrology

Volumn 26, Issue 1, 2013, Pages 55-60

  Rocha, Ana ^a   Almeida, Marta ^a   Santos, Josefina ^a   Carvalho, André ^a  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

Author keywords

Diabetes; Lactic acidosis; Metformin; Renal failure

Indexed keywords

METFORMIN;

CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG SAFETY; HUMAN; LACTIC ACIDOSIS; METFORMIN ASSOCIATED LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; WEIGHT CHANGE; WEIGHT REDUCTION;

ACIDOSIS, LACTIC; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84876358992     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000166     Document Type: Review

References (34)

1. Dell'Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD, Morgan BW. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med. 2009;54(6):818-823.
2. Peters N, Jay N, Barraud D et al. Metformin-Associated Lactic Acidosis in an Intensive Care Unit. Crit Care. 2008;12(6):R149.
3. Macias-Robles MD, Macia-Bobes C, Yano-Escudero R, Fernández-Diéguez O, Alvarez-Lecue O. Metformin-Induced Lactic Acidosis due to Acute Renal Failure. An Sist Sanit Navar. 2011;34(1):115-118.
4. Orban JC, Ghaddab A, Chatti O, Ichai C. Metfomin-Associated Lactic Acidosis. Ann Fr Anesth Reanim. 2006;25(10): 1046-1052.
5. Lalau JD. Lactic Acidosis Induced By Metformin: Incidence, Management and Prevention. Drug Saf. 2010;33(9):727-740.
6. Van Berlo-Van De Laar IR, Vermeij CG, Doorenbos CJ. Metformin Associated Lactic Acidosis: Incidence and Clinical Correlation With Metformin Serum Concentration Measurements. J Clin Pharm Ther. 2011;36(3):376-382.
7. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-Associated Lactic Acidosis: a Prognostic and Therapeutic Study. Crit Care Med. 2009;37(7):2191-2196.
8. Rifkin SI, Mcfarren C, Juvvadi R, Weinstein SS. Prolonged Hemodialysis for Severe Metformin Intoxication. Ren Fail. 2011;33(4):459-461.
9. Stades AME, Heikens JT, Erkelens DW, Holleman F, Hoekstra JBL. Metformin and Lactic Acidosis: Cause or Coincidence? A Review of Case Reports. J Intern Med. 2004;255:179-187.
10. Protti A, Russo R, Tagliabue P et al. Oxygen Consumption is depressed in Patients with Lactic Acidosis due to Biguanide Intoxication. Crit Care. 2010;14:R22.
11. Liu F, Lu J, Tang J et al. Relationship of Plasma Creatinine and Lactic Acid in Type 2 Diabetic Patients without Renal Dysfunction. Chin Med J (Engl). 2009;122(21):2547-2553.
12. Tahrani AA, Varughese GI, Scarpello JH, Hanna FWF. Metformin, Heart Failure, And Lactic Acidosis: is Metformin Absolutely Contraindicated?. BMJ. 2007;335:508-512.
13. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Review. Cochrane Database Syst Rev. 2010;(4):CD002967.
14. Nye HJ, Herrington WG. Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease? Nephron Clin Pract. 2011;118:C380-C383.
15. Sharif A. Should Metformin be our Antiglycemic Agent of Choice Post-Transplantation? Am J Transplant. 2011;11:1376-1381.
16. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, Sulfonylureas or other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. Diabetes Care. 2008; 31(11):2086-2091.
17. Salpeter SR, Greyber, E, Pasternak GA, Salpeter EE. Risk of Fatal and Nonfatal Lactic Acidosis with Metformin Use in Type 2 Diabetes Mellitus. Arch Intern Med. 2003;163(24): 2594-2602.
18. Klachko D, Whaley-Connell A. Use of Metformin in Patients with Kidney and Cardiovascular Diseases. Cardiorenal Med. 2011;1(2):87-95.
19. Carter AM, Bennett CE, Bostock JA, Grant PJ. Metformin Reduces C-Reactive Protein but not Complement Factor C3 in Overweight Patients with Type 2 Diabetes Mellitus. Diabet Med. 2005;22(9):1282-1284.
20. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.
21. American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care. 2011;34(1):S11-S61.
22. Pilmore HL. Review: Metformin: Potential Benefits and Use in Chronic Kidney Disease. Nephrology (Carlton). 2010;15(4): 412-418.
23. Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial. 2010;23(2):148-156.
24. Toyoda M, Kimura M, Yamamoto N, Miyauchi M, Umezono T, Suzuki D. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. J Nephrol. 2012 Feb 2. [Epub ahead of print]
25. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Switching from premixed insulin to glarginebased insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-carebased analysis. Cardiovasc Diabetol. 2009;8:9.
26. Lalau JD, Race JM. Lactic Acidosis in Metformine Therapy: Searching for a Link with Metformin in Reports of Metformin-Associated Lactic Acidosis. Diabetes Obes Metab. 2001;3: 195-201.
27. Frid A, Sterner GN, Löndahl M et al. Novel assay of Metformin Levels in Patients with Type 2 Diabetes and Varying Levels of Renal Function: Clinical Recommendations. Diabetes Care. 2010;33(6):1291-1293.
28. Tsuda M, Terada T, Ueba M et al. Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. J Pharmacol Exp Ther. 2009;329(1):185-191.
29. Goergen SK, Rumbold G, Compton G, Harris C. Systematic Review of Current Guidelines and their Evidence Base on Risk of Lactic Acidosis after Administration of Contrast Medium for Patients receiving Metformin. Radiology. 2010;254(1): 261-269.
30. Bhowmik D, Tiwari SC. Metabolic Syndrome and Chronic Kidney Disease. Indian J Nephrol. 2008;18(1):1-4.
31. Agrawal V, Shah A, Rice C, Franklin BA, Mccullough PA. Impact of Treating the Metabolic Syndrome on Chronic Kidney Disease. Nat Rev Nephrol. 2009;5(9):520-528.
32. Morales AI, Detaille D, Prieto M et al. Metformin prevents experimental Gentamicin-Induced Nephropathy by a Mitochondria-Dependent Pathway. Kidney Int. 2010;77(10):861-869.
33. Piwkowska A, Rogacka D, Jankowski M, Dominiczak MH, Stepiński JK, Angielski S. Metformin Induces Suppression Of NAD(P)H Oxidase Activity in Podocytes. Biochem Biophys Res Commun. 2010;393(2):268-273.
34. Thériault JR, Palmer HJ, Pittman DD. Inhibition of the Unfolded Protein Response by Metformin in Renal Proximal Tubular Epithelial Cells. Biochem Biophys Res Commun. 2011;409(3):500-505.